long intergenic non-protein coding RNA 2530Genealiases: []
Q-omics provides the consensus-scored LINC02530 profile across patient tissues and cancer cell-line models. LINC02530 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, LINC02530 is differentially expressed in 4, with the highest sampling consensus in KICH. Additionally, LINC02530 RNA expression shows 6,450 significant gene co-expression associations, with the highest sampling consensus in LIHC. Together, these results highlight ACC, KICH, and LIHC as cancer lineages where LINC02530 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC02530 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC02530 survival associations across molecular data types. LINC02530 RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC02530 RNA expression–survival associations across cancer types. High LINC02530 expression shows unfavorable associations in ACC, LIHC, READ, UCS and LUSC, but favorable associations in HNSC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for LINC02530 RNA expression.
This table summarizes LINC02530 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for LINC02530. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC02530 shows lower tumor expression in KICH, KIRC and KIRP and higher tumor expression in HNSC. The KICH box plot shows higher LINC02530 RNA expression in normal versus tumor tissue (log2 FC = −0.150, t-test p < 0.001).
This table shows molecular features associated with LINC02530 in patient tissues and cancer cell lines. In patient samples, LINC02530 shows the broadest associations at the RNA and protein expression levels, with LIHC recurring as the lineage with the largest associated feature set.
